SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

CR701 : Cervical carcinoma, adjacent tissue and adjacent normal tissue array, including TNM and pathology grade, 70 cases/70 cores

Microarray Panel	Cervical carcinoma，adjacent tissue and adjacent normal tissue array, containing 49 cases of squamous cell carcinoma, 6 adenosquamous carcinoma, 15 adjacent tissue and adjacent normal tissue, single core per case
Cores	70
Cases	70
Row number	7
Column number	10
Core Diameter (mm)	1.5
Thickness (μm)	5
QA/QC	Anti-Actin confirmed
Tissue Array Type	FFPE
Species	Human

CR701 H&E



Applications	Routine histology procedures including Immunohistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found at our support page.
Notes	1. TMA slides were sectioned and stored at 4°C and may not be fresh cut, but still suitable for IHC. Please request fresh cut if experiment involves phospho-specific antibodies, RNA studies, FISH or ISH, etc. A minimum of 3 slides per TMA must be purchased to cover the cost of trimming for fresh sectioning. 2. Most TMA slides were not coated with an extra layer of paraffin (tissue cores can be easily seen on the glass). **To prevent tissue detachment during antigen retrieval, unbaked slides must be baked for at least 30 to 120 minutes at 60°C**. before putting into xylene for de-paraffinization. Baked slides were sent out baked for 2 hours. In the following specsheet,"*" means invalid core; "-" means no applicable or negative in IHC markers.



Legend: Ute - Uterine cervix

- AT,
- Malignant tumor,
- Malignant tumor (stage 1b),
- Malignant tumor (stage I),
- Malignant tumor (stage II),
- Malignant tumor (stage III),
- Malignant tumor (stage IIIb),
- Malignant tumor (stage IIa),
- Malignant tumor (stage IVa),
- Malignant tumor (stage Ia),
- Malignant tumor (stage Ib),
- Malignant tumor (stage Ic),
- NAT

, tissue IDs are available in exported Excel files.

Pos.	No.	Age	Sex	Organ/Anatomic Site	Pathology diagnosis	TNM	Grade	Stage	Type	Image
A1	1	53	F	Uterine cervix	Squamous cell carcinoma	T1N0M0	1	I	malignant	
A2	2	69	F	Uterine cervix	Squamous cell carcinoma (sparse)	T1bN0M0	-	Ib	malignant	
A3	3	48	F	Uterine cervix	Squamous cell carcinoma	T1N0M0	2	I	malignant	
A4	4	62	F	Uterine cervix	Squamous cell carcinoma	T1N0M0	1	I	malignant	
A5	5	49	F	Uterine cervix	Squamous cell carcinoma	T1N0M0	1	I	malignant	
A6	6	65	F	Uterine cervix	Squamous cell carcinoma	T2aN0M0	1	IIa	malignant	
A7	7	51	F	Uterine cervix	Squamous cell carcinoma (sparse)	T1N0M0	1	I	malignant	
A8	8	49	F	Uterine cervix	Squamous cell carcinoma	T1N0M0	1	I	malignant	

A9	9	37	F	Uterine cervix	Squamous cell carcinoma	T1bN0M0	2	Ib	malignant	
A10	10	39	F	Uterine cervix	Squamous cell carcinoma	T4aN0M0	2	IVa	malignant	
B1	11	43	F	Uterine cervix	Squamous cell carcinoma	T1bN0M0	2	Ib	malignant	
B2	12	47	F	Uterine cervix	Squamous cell carcinoma	T2N0M0	2	II	malignant	
B3	13	68	F	Uterine cervix	Squamous cell carcinoma	T1bN0M0	2	Ib	malignant	
B4	14	47	F	Uterine cervix	Squamous cell carcinoma	T1aN0M0	2	Ia	malignant	
B5	15	36	F	Uterine cervix	Squamous cell carcinoma	T1bN1M0	1	IIIb	malignant	
B6	16	27	F	Uterine cervix	Squamous cell carcinoma	T1bN0M0	1	Ib	malignant	
B7	17	63	F	Uterine cervix	Squamous cell carcinoma	T2N0M0	1	II	malignant	
B8	18	48	F	Uterine cervix	Squamous cell carcinoma	T1bN0M0	2	Ib	malignant	
B9	19	42	F	Uterine cervix	Squamous cell carcinoma	T1bN0M0	2	Ib	malignant	
B10	20	40	F	Uterine cervix	Squamous cell carcinoma	T1N0M0	2	I	malignant	
C1	21	55	F	Uterine cervix	Squamous cell carcinoma	T1bN0M0	1	1b	malignant	
C2	22	48	F	Uterine cervix	Squamous cell carcinoma	T1N0M0	1	I	malignant	
C3	23	39	F	Uterine cervix	Squamous cell carcinoma	T1aN0M0	2	Ia	malignant	
C4	24	41	F	Uterine cervix	Squamous cell carcinoma	T1N0M0	3	I	malignant	
C5	25	62	F	Uterine cervix	Squamous cell carcinoma	T1cN0M0	2	Ic	malignant	
C6	26	46	F	Uterine cervix	Squamous cell carcinoma	T1N0M0	2	I	malignant	
C7	27	60	F	Uterine cervix	Squamous cell carcinoma	T1N0M0	2	I	malignant	
C8	28	48	F	Uterine cervix	Squamous cell carcinoma	T1N0M0	2	I	malignant	
C9	29	38	F	Uterine cervix	Squamous cell carcinoma	T2N0M0	2	II	malignant	
C10	30	48	F	Uterine cervix	Squamous cell carcinoma	T1bN0M0	2	Ib	malignant	
D1	31	56	F	Uterine cervix	Squamous cell carcinoma	T2N0M0	2	II	malignant	
D2	32	52	F	Uterine cervix	Squamous cell carcinoma	T1N0M0	3	I	malignant	
D3	33	37	F	Uterine cervix	Squamous cell carcinoma	T2N0M0	3	II	malignant	
D4	34	27	F	Uterine cervix	Squamous cell carcinoma	T1N0M0	3	I	malignant	
D5	35	58	F	Uterine cervix	Squamous cell carcinoma	T1bN0M0	3	Ib	malignant	
D6	36	41	F	Uterine cervix	Squamous cell carcinoma	T1N0M0	3	I	malignant	
D7	37	61	F	Uterine cervix	Squamous cell carcinoma	T1bN0M0	3	Ib	malignant	
D8	38	45	F	Uterine cervix	Squamous cell carcinoma	T2N0M0	2	II	malignant	
D9	39	34	F	Uterine cervix	Squamous cell carcinoma	T1N0M0	3	I	malignant	
D10	40	45	F	Uterine cervix	Squamous cell carcinoma	T1N0M0	2	I	malignant	
E1	41	50	F	Uterine cervix	Squamous cell carcinoma	T1N0M0	3	I	malignant	
E2	42	65	F	Uterine cervix	Squamous cell carcinoma	T1bN0M0	3	Ib	malignant	
E3	43	48	F	Uterine cervix	Squamous cell carcinoma	T1bN0M0	3	Ib	malignant	
E4	44	51	F	Uterine cervix	Squamous cell carcinoma	T1bN0M0	3	Ib	malignant	
E5	45	32	F	Uterine cervix	Squamous cell carcinoma	T1N0M0	3	I	malignant	
E6	46	50	F	Uterine cervix	Squamous cell carcinoma	T1N0M0	3	I	malignant	
E7	47	37	F	Uterine cervix	Squamous cell carcinoma	T1bN0M0	3	Ib	malignant	
E8	48	27	F	Uterine cervix	Squamous cell carcinoma	T1bN0M0	3	Ib	malignant	
E9	49	32	F	Uterine cervix	Squamous cell carcinoma	T1aN0M0	3	Ia	malignant	
E10	50	43	F	Uterine cervix	Adenosquamous carcinoma	T2N0M0	-	II	malignant	
F1	51	42	F	Uterine cervix	Adenosquamous carcinoma	T1aN0M0	-	Ia	malignant	
F2	52	54	F	Uterine cervix	Adenosquamous carcinoma	T1bN0M0	-	Ib	malignant	
F3	53	48	F	Uterine cervix	Adenosquamous carcinoma	T3N0M0	-	III	malignant	
F4	54	42	F	Uterine cervix	Adenosquamous carcinoma	T2aN0M0	-	IIa	malignant	
F5	55	43	F	Uterine cervix	Adenosquamous carcinoma	T1aN0M0	-	Ia	malignant	
F6	56	40	F	Uterine cervix	Cancer adjacent tissue (chronic cervicitis)	-	-	-	AT	
F7	57	49	F	Uterine cervix	Cancer adjacent normal cervical canals tissue	-	-	-	NAT	
F8	58	35	F	Uterine cervix	Cancer adjacent normal cervical canals tissue	-	-	-	NAT	
F9	59	32	F	Uterine cervix	Cancer adjacent cervical canals tissue (chroni c inflammation)	-	-	-	AT	
F10	60	40	F	Uterine cervix	Cancer adjacent normal cervical canals tissue	-	-	-	NAT	
G1	61	40	F	Uterine cervix	Cancer adjacent tissue (chronic cervicitis)	-	-	-	AT	
G2	62	32	F	Uterine cervix	Cancer adjacent normal cervix tissue	-	-	-	NAT	
G3	63	46	F	Uterine cervix	Cancer adjacent tissue (chronic cervicitis)	-	-	-	AT	
G4	64	37	F	Uterine cervix	Cancer adjacent normal cervix tissue	-	-	-	NAT	

G5	65	51	F	Uterine cervix	Cancer adjacent tissue (chronic cervicitis)	-	-	-	AT
G6	66	41	F	Uterine cervix	Cancer adjacent normal cervix tissue	-	-	-	NAT
G7	67	42	F	Uterine cervix	Cancer adjacent tissue (chronic cervicitis with squamous epithelium hyperplasia)	-	-	-	AT
G8	68	31	F	Uterine cervix	Cancer adjacent normal cervix tissue	-	-	-	NAT
G9	69	48	F	Uterine cervix	Cancer adjacent normal cervix tissue	-	-	-	NAT
G10	70	41	F	Uterine cervix	Cancer adjacent normal cervical canals tissue	-	-	-	NAT
-	0	55	F	liver	Hepatocellular liver cancer (tissue marker)	T3N0M0	3		Malignant

TNM grading:

T - Primary tumor

Tx - Primary tumor cannot be assessed
T0 - No evidence of primary tumor
Tis - Carcinoma in situ; intraepithelial or invasion of lamina propria
T1 - Tumor invades submucosa
T2 - Tumor invades muscularis propria
T3 - Tumor invades through muscularis propria into subserosa or into non-peritonealized pericolic or perirectal tissues.
T4 - Tumor directly invades other organs or structures and/or perforate visceral peritoneum

N - Regional lymph nodes

Nx - Regional lymph nodes cannot be assessed
N0 - No regional lymph node metastasis
N1 - Metastasis in 1 to 3 regional lymph nodes
N2 - Metastasis in 4 or more regional lymph nodes

M - Distant metastasis

Mx - Distant metastasis cannot be assessed
M0 - No distant metastasis
M1 - Distant metastasis

UK & Rest of the World
184 Park Drive, Milton Park
Abingdon OX14 4SE, U.K.
T: +44 (0) 1235 828 200
F: +44 (0) 1235 820 482

North America
1035 Cambridge Street,
Cambridge, MA 02141.
T: +1 (617) 945-5033 or
T: +1 (800) 987-0985
F: +1 (617) 945-8218

Germany
Bockenheimer Landstr. 17/19
60325 Frankfurt/Main
T: +49 (0) 69 779099
F: +49 (0) 69 13376880

Switzerland
Via Lisano 3
(CP.683)
6900 Massagno
T: +41 (0) 91 604 55 22
F: +41 (0) 91 605 17 85